Study to Analyze the Efficacy of Chronic Intake With a β-alanine Supplement in Recreational Cyclists (B-AC2)

Universidad Católica San Antonio de Murcia

Status: Completed

Conditions: Beta Alanine Supplementation

Treatments: Dietary Supplement: Beta Alanine low dose; Dietary Supplement: Beta Alanine high dose; Other: Control group

Study type: Interventional

Funder types: Other

Identifiers

NCT06191055

UCAMCFE-00030

Details and patient eligibility

About

Randomized, controlled, double-blind, single-center, controlled clinical trial with three parallel arms depending on the product consumed (experimental product dose 1 and dose 2 and placebo product) to measure the efficacy of 28-day consumption of a sustained-release beta alanine on the physiological efficacy of physical performance in recreational cyclists.

Full description

Subjects meeting the selection criteria will be randomly assigned to each of the study groups (investigational product dose 1 or dose 2, or placebo, depending on the group to which they have been assigned).

The product to be consumed is beta alanine. Participants will consume the product for 28 days. They will have to take 4 intakes every three hours, the first intake being two hours after waking up.

The study subjects will have to make 2 visits to the laboratory. Physical performance and physiological changes will be evaluated with a 10-minute time trial. The first test will be performed without product consumption and the second after 28 days of consumption.

Enrollment: 75 patients

Sex: Male

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male cyclists with more than two years of cycling experience.
• Perform tests without fatigue.
• Road bike training at least twice a week.

Exclusion criteria

• Participants with chronic illness.
• Have a long-term injury that prevents you from training in the previous month.
• Inability to understand informed consent.
• Have consumed beta alanine in the three years prior to the start of the study.
• Consumption of other supplements that may alter performance.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

75 participants in 3 patient groups, including a placebo group

Beta Alanine high dose

Experimental group

Description:

Consumption for 28 days.

Treatment:

Dietary Supplement: Beta Alanine high dose

Beta Alanine low dose

Experimental group

Description:

Consumption for 28 days.

Treatment:

Dietary Supplement: Beta Alanine low dose

Control group

Placebo Comparator group

Description:

Consumption for 28 days.

Treatment:

Other: Control group